

REPORT TO:	BOARD OF DIRECTORS (BoD)				
REPORT TITLE:	INTEGRATED PERFORMANCE REPORT (IPR)				
MEETING DATE:	6 OCTOBER 2022				
BOARD SPONSOR:	CHIEF FINANCE OFFICER				
PAPER AUTHOR:	CHIEF FINANCE OFFICER				
APPENDICES:	APPENDIX 1: AUGUST 2022 IPR				
<b>Executive Summary:</b>					
Action Required:	Decision Approval Information Assurance Discussion				
(Highlight one only)	Approval Information Accordance Discussion				
Purpose of the	The Trust has been engaged with a quality improvement				
Report:	The Trust has been engaged with a quality improvement programme called "We Care". The premise is that the Trust will focus on fewer metrics but in return will expect to see a greater improvement (inch wide, mile deep). This report is updated for the key metrics that the Trust will focus on in 2022/23.				
Summary of Key Issues:	The attached IPR is now ordered into the following:				
	True Norths- These are the Trust wide key strategic objectives which it aims to have significant improvements on over the next 5 years, as these are challenging targets over a number of years it may be that the targets are not met immediately and it is important to look at longer term trajectories. The areas are:  • our quality and safety. The two metrics the Trust has chosen to measure against incidents with harm and mortality rate.  • our patients. The four metrics being measured are the Cancer 62-day target, the Accident & Emergency (A&E) over 12-hour target, the Referral to Treatment (RTT) 18-week target and the Friends and Family recommended %.  • our people. The one metric chosen is for staff engagement.  • our sustainability. The two metrics chosen to improve are the Trust's financial position and carbon footprint.  • our future. The two metrics chosen are the medically fit for discharge % and virtual outpatients usage.  Breakthrough objectives- These are objectives that we are driving over the next year and are looking for rapid improvement. The four key areas are:  • Improving theatre capacity. The lost theatre opportunities in month was 43 which is worse than the 25 target and is 9 worse than last month. Cancellations on day also had a slight increase from 147 in July to 167 in August.  • Utilising all of our available theatre sessions and returning to pre-covid cases per session (2.8) will enable us to treat more patients and reduce waiting times for patients waiting for surgical treatment. The current cases per session is at 2.3. To facilitate this there are a number of measures that have been implemented, with further action required:  • We are optimising scheduling opportunities with the booking teams. This includes awareness of individual targets and discrepancies between planned and actual utilisation; August booking performance at 85.2%, with actual theatre occupancy at 78.4%.				



- The 2022/23 elective activity plan has been translated into weekly sessions required, and has been used in the development of the revised theatres timetable which went live on 5 September. As such, theatre time will be proportionate to the activity required by each speciality.
- The theatre staffing business case will be presented at Clinical Executive Management Group (CEMG) in October, recruitment at risk is underway.
- The theatre optimisation group was established in August and meets fortnightly and is drawing up plans and Standard Operating Procedures (SOPs) regarding Implementation of 6:4:2 and theatre utilisation meetings, led by the Surgery & Anaesthetics Leadership team.
- There has been a focus on aligning sub specialities within orthopaedics to the theatre timetable and an away day with the consultants has concentrated on work to increase cases per list and efficiencies through the Elective Orthopaedic Centre.
- Same Day Emergency Care (SDEC) Admissions. The SDEC activity across all services deteriorated in August 2022 (1875 v 2032 in July), with Paediatrics reporting 116 seen in August v 181 in July. Medicine also reported a reduced footfall accessing the service (73% against the activity seen in March 2022) though remains above trajectory with no deterioration in the % of patients discharged. Frailty also remains above trajectory but further analysis on length of stay, discharge % is to be undertaken now the Queen Elizabeth the Queen Mother Hospital (QEQM) has established its frailty unit at the front door in September 2022.
- A clinical forum with clinical leads delivering SDEC was held with community partners and identified next steps to progress the SDEC services:
  - A clear ambition to work this through to fully realise the opportunity, to consider joint SDEC models of care, equitable across all sites, planning ahead of the Emergency Department (ED) build completion.
  - Establish an away day with clinical leads for both SDEC/Integrated SDEC and Direct Access pathways to be planned (29 September confirmed).
- **Staff Involvement.** The current staff involvement score has remained at 6.28 in month with an aim to reach 6.8 by the end of 2022/23.
- 20 areas have now been trained as part of the Team Engagement and Development (TED) pilot, including Cardiology and Rheumatology, with a further 16 planned before the end of November.
- The We Care rollout has been extended beyond the 20 'units' surveyed in July as part of the National Quarterly Pulse Survey (NQPS) and will also include Urology and Cardiology.
- Two of the priority areas identified as part of the National Staff Survey (NSS) data review (those with the lowest scores for involvement) are completing KENT Fundamentals in September.
- The new staff intranet, Interact, has been reviewed and can provide; sentiment analysis, target pulse surveys and an online suggestion area, the effectiveness of which will be piloted.



		<ul> <li>An 'Involvement Toolkit' is being finalised to provided support at team leader, speciality and Care Group level throughout the NSS.</li> <li>Premium Pay costs. The Trust spends £87m per annum on premium pay with an aim to reduce this by 10% over the year. In month premium pay was £8.8m an increase of £0.1m from July. The premium pay position is impacted by the opening of escalation areas across the Trust.</li> <li>The Executive team are continuing their focus in this area as this is a key contributor to the financial position.</li> <li>Key Interventions include: <ul> <li>Formalising and strengthening the weekly premium pay meeting.</li> <li>Detailed focus by Care Groups on drivers of premium pay. Premium pay deep dives occurring through September.</li> <li>Review of bank, agency and overtime rates across all staff groups.</li> <li>Ensure improved sign off processes and governance across the Trust.</li> <li>Recruitment to key clinical posts to reduce the need for temporary staffing.</li> </ul> </li> </ul>							
Key Recommendation(s):		Watch Metrics - these are metrics we are keeping an eye on to ensure they don't deteriorate.  The Board of Directors is asked to CONSIDER and DISCUSS the True North and Breakthrough Objectives of the Trust.							
Implications:									
Implications: Links to 'We Care' Strategic Objectives:									
Links to 'We Car	e' Strate	egic Objectiv	es:						
Cur patients	e' Strate Our pe	•	es: Our future	Our sustainability	Our quality and safety				
	Our pe	BAF 32: The high standard delivered, lead of stay, loss or resulting in recare.  BAF 34: Fail due to the fluinecessitating BAF 31: Fail (HCAI) cases associated wharm, includi		sustainability ntial or actual harm rovement workstre nt outcomes with e patients, families a the Trust and add operational constitute Covid-19 pand we to prioritise P1 idable healthcare a eportable organism ements and Covid- s of externally set	and safety n to patients if eams are not extended length and carers ditional costs to utional standards demic and P2 patients. associated ms, infections d-19, leading to objectives,				
Our patients  Link to the Board Assurance	Our pe	BAF 32: The high standard delivered, lead of stay, loss of resulting in recare.  BAF 34: Fail due to the fluinecessitating BAF 31: Fail (HCAI) cases associated wharm, including possible regulations of the fluinecessitation of the fluinecessitatio	Our future  Tre is a risk of potents of care and imple ading to poor patients of confidence with a putational harm to be used to be a localised direction of infection with right statutory requiring death, breached alatory action, prosessor patient experience is a risk that patents of the poor patient of the poor patient experience is a risk that patents of the poor patient experience is a risk that patents of the poor patient experience is a risk that patents of the poor patient experience is a risk that patents of the poor patient experience is a risk that patents of the poor patient experience is a risk that patents of the poor patient experience is a risk that patents of the poor patient experience is a risk that patents of the poor patients of the poo	sustainability ntial or actual harn rovement workstre nt outcomes with e patients, families a the Trust and add operational constitute Covid-19 pand we to prioritise P1 idable healthcare a eportable organism ements and Covid s of externally set accution, litigation a may receive sub-op ce in our maternity tients do not recei	and safety n to patients if eams are not extended length and carers ditional costs to utional standards demic and P2 patients. associated ms, infections d-19, leading to objectives, and reputational otimal quality of v services.				
Our patients  Link to the Board Assurance Framework (BAF)  Link to the Corporation Risk Register (Care)	Our pe	BAF 32: The high standard delivered, lead of stay, loss of resulting in recare.  BAF 34: Fail due to the fluinecessitating BAF 31: Fail (HCAI) cases associated wharm, including possible regulations of the emergency N	Our future  Tre is a risk of poteds of care and impleding to poor patie of confidence with eputational harm to ure to deliver the control of a localised direction with routh statutory requiring death, breached alatory action, prosent and babies mor patient experience.	sustainability ntial or actual harn rovement workstre nt outcomes with e patients, families a the Trust and add operational constitute Covid-19 pand we to prioritise P1 idable healthcare a eportable organism ements and Covid s of externally set accution, litigation a may receive sub-op ce in our maternity tients do not recei	and safety n to patients if eams are not extended length and carers ditional costs to utional standards demic and P2 patients. associated ms, infections d-19, leading to objectives, and reputational otimal quality of v services.				
Our patients  Link to the Board Assurance Framework (BAF)  Link to the Corporation Risk Register (Cartes)  Resource: Legal and regulated Subsidiary:	Our pe	BAF 32: The high standard delivered, lead of stay, loss of resulting in recare.  BAF 34: Fail due to the fluinecessitating BAF 31: Fail (HCAI) cases associated wharm, including possible regulations of the emergency North N	Our future  Tre is a risk of potents of care and imple ading to poor patients of confidence with a putational harm to be used to be a localised direction of infection with right statutory requiring death, breached alatory action, prosessor patient experience is a risk that patents of the poor patient of the poor patient experience is a risk that patents of the poor patient experience is a risk that patents of the poor patient experience is a risk that patents of the poor patient experience is a risk that patents of the poor patient experience is a risk that patents of the poor patient experience is a risk that patents of the poor patient experience is a risk that patents of the poor patient experience is a risk that patents of the poor patients of the poo	sustainability ntial or actual harn rovement workstre nt outcomes with e patients, families a the Trust and add operational constitute Covid-19 pand ve to prioritise P1 idable healthcare a eportable organism ements and Covid s of externally set secution, litigation a may receive sub-op ce in our maternity tients do not recei D.	and safety n to patients if eams are not extended length and carers ditional costs to utional standards demic and P2 patients. associated ms, infections d-19, leading to objectives, and reputational etimal quality of or services. In the patients of the p				
Our patients  Link to the Board Assurance Framework (BAF)  Link to the Corporation Risk Register (Cartesian Resource:  Legal and regula	Our pe	BAF 32: The high standard delivered, lead of stay, loss of resulting in recare.  BAF 34: Fail due to the fluinecessitating BAF 31: Fail (HCAI) cases associated wharm, including possible regulations of the emergency North N	our future  Tre is a risk of potents of care and imple ading to poor patient of confidence with apputational harm to the cure to deliver the cure to deliver the cure to prevent avoid of infection with right statutory requiring death, breached alatory action, prosents a risk that pay care within the Eximple the cure is a risk that pay care within the cure is a risk that pay care within the Eximple the cure is a risk that pay care w	sustainability ntial or actual harn rovement workstre nt outcomes with e patients, families a the Trust and add operational constitute Covid-19 pand ve to prioritise P1 idable healthcare a eportable organism ements and Covid s of externally set secution, litigation a may receive sub-op ce in our maternity tients do not recei D.  ne subsidiaries the	and safety n to patients if eams are not extended length and carers ditional costs to utional standards demic and P2 patients. associated ms, infections d-19, leading to objectives, and reputational etimal quality of v services. ive timely access				